Carolyn Bertozzi

Enable Biosciences Appoints Will Robberts as Chief Financial Officer and Secures Strategic Funding

Retrieved on: 
Thursday, April 4, 2024
KPMG, Thomson Reuters, Growth, Health, CFO, SAN, University, Software, Doctor of Philosophy, Stanford University, Financial management, Bachelor, Enabling, Economics, University of California, Berkeley, Carolyn Bertozzi, Management

"We are thrilled to welcome Will Robberts as our new CFO," said David Seftel, M,D.

Key Points: 
  • "We are thrilled to welcome Will Robberts as our new CFO," said David Seftel, M,D.
  • "His extensive experience and proven track record in finance and operations make him an invaluable addition to our leadership team.
  • He has already significantly impacted the business by securing pivotal funding for the company to support key strategic initiatives."
  • A graduate of the University of Johannesburg, Will holds Bachelor's, Honors, and Master's degrees in Accounting, Economics, and Financial Management.

Enable Biosciences Receives Accreditation From The College Of American Pathologists

Retrieved on: 
Tuesday, March 19, 2024
College, Risk, Patient, SAN, Accreditation, CAP, Laboratory, MD, Carolyn Bertozzi, ASCP, DPH, Health

SOUTH SAN FRANCISCO, Calif., March 19, 2024 /PRNewswire/ -- The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Enable Biosciences Clinical Reference Laboratory in South San Francisco, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 19, 2024 /PRNewswire/ -- The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Enable Biosciences Clinical Reference Laboratory in South San Francisco, California, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
  • Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient outcomes.
  • Enable Biosciences is now among more than 8,000 CAP-accredited facilities worldwide.
  • "This accreditation underscores our commitment to providing the highest quality diagnostic services," said Lynette Sawyer, reflecting on the achievement.

Enable Biosciences Publishes Study Revealing ADAP Technology's Improved Accuracy in T1D Risk Prediction

Retrieved on: 
Tuesday, February 13, 2024
ADAP, SAN, Real-time, Doctor of Philosophy, NPV, PPV, Laboratory developed test, Risk, Autoantibody, Carolyn Bertozzi, Risk assessment, CLIA, RBA, T1D, CAP, NIDDK, Public, Pharmaceutical industry

Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.

Key Points: 
  • Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.
  • This pivotal study underscores the ADAP assay's ability to detect islet autoantibodies, which are indicative of a high risk of progression to clinical T1D.
  • Dr. Jason Tsai, PhD, CTO of Enable Biosciences, elaborates on the significance of the findings: "These study results reinforce the strength of our ADAP technology in early T1D detection.
  • For more insights into Enable Biosciences and the impact of their ADAP technology, please visit www.enablebiosciences.com .

Enable Biosciences Inc. Reveals Key Findings on COVID-19 Transmission from Mothers to Newborns

Retrieved on: 
Wednesday, January 3, 2024
Carolyn Bertozzi, Antibody, Research, Prevalence, SAN, Prenatal development, Infection, California Department, ADAP, COVID, COVID-19, Public, SARS-CoV-2, Longevity, Public health, Canadian International Council, Projection screen, Vaccine

This research is crucial in understanding how maternal antibodies against SARS-CoV-2 are transferred to and persist in newborns.

Key Points: 
  • This research is crucial in understanding how maternal antibodies against SARS-CoV-2 are transferred to and persist in newborns.
  • The study involved analyzing dried blood spots from newborns for the presence of these antibodies.
  • With 15.7% of newborns testing positive, the study provides new insights into the prevalence and longevity of maternal antibodies, highlighting a significant maternal transmission rate.
  • Dr. Jason Tsai, CTO of Enable Biosciences, commented, "This study is a landmark in neonatal research, offering unprecedented insights into maternal-to-neonatal antibody transfer.

Enable Biosciences Receives $3M Phase IIB SBIR Award from NIDDK for Advanced T1D Testing Technology

Retrieved on: 
Tuesday, December 19, 2023
Carolyn Bertozzi, Autoantibody, Risk, SBIR, Validation, FDA, Digestive, Disease, Kidney, SAN, Doctor of Philosophy, NIDDK, Type 1 diabetes, ADAP, Safety

A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.

Key Points: 
  • A key objective of this funding is to pursue FDA clearance for the T1D test, a critical step towards commercialization.
  • Dr. Jason Tsai, PhD, Chief Technical Officer at Enable Biosciences, shared his enthusiasm: "This Phase IIB SBIR award from NIDDK is a testament to our dedication to transforming T1D testing.
  • The NIDDK's support is pivotal for Enable Biosciences in its pursuit of FDA clearance for its innovative T1D test.
  • For more information about Enable Biosciences and their cutting-edge approach to T1D testing, visit www.enablebiosciences.com or contact their media team for further details and inquiries.

InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association

Retrieved on: 
Friday, October 13, 2023
Technology, Medical Devices, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Artificial Intelligence, Oncology, Diagnosis, NN, Partnership, Biomarker, Biology, Colorectal cancer, Receiver, CRC, Artificial intelligence, Workflow, Patient, AA, American Gastroenterological Association, Carolyn Bertozzi, Shaukat Khanum Memorial Cancer Hospital and Research Centre, LC-MS, Data analysis, Operating point, FP, Cancer, Research, Pharmaceutical industry, Medical imaging, Gastroenterology

InterVenn Biosciences , a life sciences company pioneering glycoproteomics, today announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.

Key Points: 
  • InterVenn Biosciences , a life sciences company pioneering glycoproteomics, today announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.
  • This groundbreaking research in early detection of CRC represents an advancement in early diagnosis through serum glycoproteome profiling.
  • The results published in Gastroenterology establish the groundwork for a blood-based CRC screening modality using artificial intelligence to reveal the earliest stages of colorectal cancer.
  • Desai K, Gupta S, May FP, Xu G, Shaukat A, Hommes DW, NICE-AA/CRC- Consortium, Early detection of advanced adenomas and colorectal carcinoma by serum glycoproteome profiling., Gastroenterology (2023), doi: https://doi.org/10.1053/j.gastro.2023.09.034

InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

Retrieved on: 
Wednesday, September 27, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Technology, Other Technology, Interim, NGS, Medicines and Healthcare products Regulatory Agency, Liquid biopsy, Carolyn Bertozzi, Multimedia, Medication, Pharmaceuticals and Medical Devices Agency, RUO, Acquisition, Patient, IVD, Growth, Management, Medical imaging, Oncology, Archery

InterVenn Biosciences , the life sciences company pioneering glycoproteomic-based diagnostics, today announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.

Key Points: 
  • InterVenn Biosciences , the life sciences company pioneering glycoproteomic-based diagnostics, today announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.
  • View the full release here: https://www.businesswire.com/news/home/20230927452734/en/
    Joshua Stahl has been appointed as Chief Executive Officer to guide InterVenn's next phase of commercial growth.
  • (Photo: Business Wire)
    Mr. Stahl has a proven track record of building successful diagnostics companies.
  • Throughout his tenure, Mr. Stahl held leadership roles with increasing responsibility before becoming Chief Scientific Officer and Chief Operating Officer.

InterVenn Demonstrates Power of Its GlycoVision™ Platform In Advanced Adenoma and Colorectal Cancer

Retrieved on: 
Monday, May 8, 2023
Software, Research, Pharmaceutical, Hardware, Oncology, Medical Devices, Technology, Artificial Intelligence, Science, Biotechnology, Other Science, Health, DNA, Glycoprotein, Therapy, CRC, Serum, Liquid biopsy, Carolyn Bertozzi, Multimedia, Mass spectrometry, Doctor of Philosophy, Circulating free DNA, Adenoma, DDW, Plasma, Conditional sentence, CTC, MD, Patient, Risk, Colorectal cancer, LC-MS, Neoplasm, Glycosylation, Medical imaging, AA

This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™ , analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC).

Key Points: 
  • This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™ , analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC).
  • Separately, AA (N=32) was predicted with 87.5% sensitivity and CRC with 89.4% sensitivity.
  • The sensitivity results of 87.5% for AA prediction is the highest that has been reported to date in the industry.
  • To put simply, we’ve known for some time of the possibility to detect AA at the pre-cancer stage,” said Daniel Hommes, MD, PhD, gastroenterologist, and Chief Medical Officer at InterVenn.

InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023

Retrieved on: 
Wednesday, April 19, 2023
Oncology, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Biotechnology, Abstract, DNA, Circulating tumor DNA, Glycoprotein, CRC, Serum, Carolyn Bertozzi, American Gastroenterological Association, Adenoma, DDW, AGA, MD, Patient, Cancer, Colorectal cancer, Colonoscopy, Mortality, Neoplasm, Conference, AA, Disease, Pharmaceutical industry, Medical imaging

InterVenn Biosciences , the life science company pioneering glycoproteomics, today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).

Key Points: 
  • InterVenn Biosciences , the life science company pioneering glycoproteomics, today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).
  • The data will be presented as a “Poster of Distinction" at the 2023 Digestive Disease Week Conference (DDW), being held May 6-9, in Chicago, IL.
  • GlycoVision’s method of assessing circulating serum glycoproteins is unlike any non-invasive test for CRC that’s on the market, which primarily rely on circulating tumor DNA (ctDNA).
  • Details on the time and location of the presentation are as follows:
    Warning Signs from the Crypt: Circulating Aberrant Glycosylation Signatures Correlate with Advanced Adenoma and Colorectal Cancer

Enable Biosciences Announces Relaunch of Website for Early Detection of Type 1 Diabetes

Retrieved on: 
Tuesday, March 21, 2023
Carolyn Bertozzi, JDRF, Teplizumab, T1D, Research, MD, SAN, Immune system, Autoimmune disease, Sanofi, Health, Autoantibody, Disease, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., March 21, 2023 /PRNewswire/ -- Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2023 /PRNewswire/ -- Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.
  • Type 1 diabetes is an autoimmune disease affecting over 1.6 million people in the United States.
  • The relaunch of the site coincides with the approval of a new therapy for type 1 diabetes.
  • The Enable Biosciences website is now live and accepting orders for the early detection testing kit.